You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Drugs Containing Excipient (Inactive Ingredient) 2,4-DIHYDROXYBENZOIC ACID


✉ Email this page to a colleague

« Back to Dashboard


2,4-DIHYDROXYBENZOIC ACID Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for the Pharmaceutical Excipient: 2,4-Dihydroxybenzoic Acid

Introduction

2,4-Dihydroxybenzoic acid, also known as β-resorcylic acid, is a dihydroxybenzoic acid that has garnered significant attention in various scientific and industrial fields, including pharmaceuticals. This compound, with its unique chemical properties, is increasingly being utilized as a pharmaceutical excipient. Here, we delve into the market dynamics and financial trajectory of 2,4-dihydroxybenzoic acid as a pharmaceutical excipient.

Chemical Properties and Synthesis

2,4-Dihydroxybenzoic acid has a chemical formula of C7H6O4 and a molar mass of 154.12 g/mol. It is synthesized via the Kolbe-Schmitt reaction from resorcinol, a process that highlights its potential for large-scale production[1][2].

Applications in Pharmaceuticals

Role as an Excipient

Pharmaceutical excipients like 2,4-dihydroxybenzoic acid play a crucial role in enhancing the solubility, bioavailability, and stability of active pharmaceutical ingredients (APIs). The growing demand for innovative excipients, driven by the rise in chronic diseases, positions 2,4-dihydroxybenzoic acid as a valuable component in modern drug formulations[3].

Biological and Chemical Uses

This compound is used in the synthesis of various pharmaceuticals, such as mycophenolic acid and hydroxylated and prenylated xanthones, which have antitumor properties. Additionally, it is involved in the production of resorcinol-based N-benzyl benzamide derivatives, which act as potent Hsp90 inhibitors[2].

Market Dynamics

Global Market Trends

The global pharmaceutical excipients market is expected to grow from $9.7 billion in 2024 to $12.4 billion by 2029, at a compound annual growth rate (CAGR) of 5.1%. This growth is driven by the increasing need for effective and patient-friendly drug formulations, particularly in the context of rising chronic diseases[3].

Demand and Supply

The demand for 2,4-dihydroxybenzoic acid is anticipated to increase due to its versatility in pharmaceutical applications. Companies like Sigma-Aldrich, which supply high-purity forms of this compound, are likely to benefit from this growing demand. The supply chain, however, must navigate challenges such as regulatory compliance, geopolitical instability, and raw material shortages[2][3].

Financial Trajectory

Market Size and Growth

The market for 2,4-dihydroxybenzoic acid is expected to experience robust growth rates, aligned with the overall pharmaceutical excipients market. The positive trend in market dynamics suggests that this compound will be a significant contributor to the financial performance of companies involved in its production and distribution[4].

Revenue Projections

Given the projected growth of the pharmaceutical excipients market, companies that specialize in 2,4-dihydroxybenzoic acid can anticipate increased revenue. For instance, if the global market grows to $12.4 billion by 2029, a significant portion of this growth could be attributed to the demand for specialized excipients like 2,4-dihydroxybenzoic acid.

Investment and Innovation

Leading companies in the pharmaceutical excipients market are investing heavily in research and development to drive innovation and sustainability. Strategic alliances, research collaborations, and acquisitions are key strategies these companies are employing to expand their product portfolios and enhance their market presence. This investment is likely to further boost the financial trajectory of 2,4-dihydroxybenzoic acid as a pharmaceutical excipient[3].

Challenges and Opportunities

Regulatory Environment

One of the primary challenges facing the pharmaceutical excipients market, including 2,4-dihydroxybenzoic acid, is the stringent regulatory environment. Compliance with these regulations requires significant investment in research and testing, which can be a barrier to entry for smaller market players[3].

Sustainability and Innovation

Despite the challenges, the future of pharmaceutical excipients is filled with opportunities. The growing emphasis on personalized medicine and precision therapeutics will drive demand for tailored excipient solutions, including 2,4-dihydroxybenzoic acid. Companies that invest in cutting-edge technologies and sustainable practices are likely to set new standards for the industry and pave the way for future advancements[3].

Industry Players and Market Presence

Key Companies

Companies such as Sigma-Aldrich, BASF SE, Roquette Frères, Ashland Global, and Croda International Plc are pivotal in shaping the evolution of the pharmaceutical excipients market. These companies leverage their expertise and resources to drive innovation and expand their product portfolios, which includes compounds like 2,4-dihydroxybenzoic acid[3].

Conclusion

The market dynamics and financial trajectory for 2,4-dihydroxybenzoic acid as a pharmaceutical excipient are highly promising. Driven by the growing demand for innovative excipients, this compound is set to play a significant role in the pharmaceutical industry. Despite the challenges posed by regulatory environments and supply chain disruptions, the future looks bright for companies investing in this area.

Key Takeaways

  • Growing Demand: The demand for 2,4-dihydroxybenzoic acid is increasing due to its applications in pharmaceutical formulations.
  • Market Growth: The global pharmaceutical excipients market is projected to grow significantly, with 2,4-dihydroxybenzoic acid contributing to this growth.
  • Regulatory Challenges: Compliance with stringent regulations is a significant challenge for companies producing this compound.
  • Innovation and Sustainability: Investment in cutting-edge technologies and sustainable practices is crucial for future growth.
  • Industry Players: Key companies are driving innovation and expanding their product portfolios to include 2,4-dihydroxybenzoic acid.

FAQs

Q1: What is the chemical formula of 2,4-dihydroxybenzoic acid?

The chemical formula of 2,4-dihydroxybenzoic acid is C7H6O4[1].

Q2: How is 2,4-dihydroxybenzoic acid synthesized?

It is synthesized via the Kolbe-Schmitt reaction from resorcinol[1][2].

Q3: What are the primary applications of 2,4-dihydroxybenzoic acid in pharmaceuticals?

It is used to enhance the solubility, bioavailability, and stability of APIs, and in the synthesis of various pharmaceutical compounds such as mycophenolic acid and hydroxylated xanthones[2].

Q4: What are the challenges facing the market for 2,4-dihydroxybenzoic acid?

The primary challenges include a stringent regulatory environment, geopolitical instability, and raw material shortages[3].

Q5: Which companies are key players in the market for 2,4-dihydroxybenzoic acid?

Key companies include Sigma-Aldrich, BASF SE, Roquette Frères, Ashland Global, and Croda International Plc[3].

References

  1. Wikipedia: 2,4-Dihydroxybenzoic acid.
  2. Sigma-Aldrich: 2,4-Dihydroxybenzoic acid 97.
  3. BCC Research: Understanding the Future of Pharmaceutical Excipients.
  4. Market Research Intellect: 2,4-Dihydroxybenzoic Acid Market Size, Scope And Forecast Report.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.